The seminar presents crystallographic fragment screening as a way to identify new chemical scaffolds for antimalarial drug development. The focus is Plasmodium falciparum lysyl-tRNA synthetase, a high-priority malaria target validated by biological and chemical approaches, and the use of XChem technology to develop new hit series
About the speaker
Dr Lizbé Koekemoer completed postdoctoral work at the University of Cape Town in South Africa and joined the Structural Genomics Consortium (SGC) in 2019 to learn structure-based drug design. She is a team leader and protein crystallography small research facility (PX-SRF) coordinator at the Centre for Medicines Discovery, University of Oxford
